Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the
“Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA
manufacturing and nucleic acid-based technologies, today announced
signing a mutual collaboration agreement (the “Agreement”) with
Ganesha Ecosphere Ltd. (BSE: GANECOS) (Ganesha), the largest
recycled polyester (rPET) fiber producer in India with over
300-plus customers, 250-plus suppliers, and 500-plus product
variants. Under the terms of the Agreement, Ganesha will deploy the
CertainT® platform, Applied DNA’s traceability system, to tag an
initial pilot production of recycled polyester (rPET) at Ganesha’s
facilities in India and conduct confirmatory samples testing at
Applied DNA’s laboratories in India and the U.S. The collaboration
between the two companies will provide brands and textile
manufacturers with a trusted solution to support their
sustainability goals for rPET and confirm raw material authenticity
at all stages of the textile value chain.
The Agreement enables Ganesha to introduce and apply
CertainT-verified rPET to provide assurance for the raw material
with textile and apparel customers. Ganesha will also employ
Applied DNA’s recently introduced SigNature® T-100 tracer system
that enables rPET source material to be quantified in polyester
blends by the CertainT platform. SigNature T-100 is a proprietary
molecular-based tracer system used to identify, analyze, and verify
rPET, polypropylene, acrylic, and potentially other man-made
materials for claims of both identification and quantification of
the raw material tagged and subsequently spun into yarn for various
textile products.
“Traceability has now added more authenticity and credibility to
the entire textile supply chain and is becoming an integral part of
the recycling process. With Applied DNA and CertainT, our customers
can now trust in the original tagged synthetic fiber and verify
product-related sustainability claims,” stated Mr. B.P. Sultania,
Joint President of Ganesha Ecosphere Ltd.
Since entering the rPET business in 1994, Ganesha has pioneered
the manufacturing of rPET fiber and rPET yarn from post-consumer
PET bottle scrap under the leadership and vision of Chairman Shri
Shyam Sunder Sharmma. The company is the largest producer of rPET
fiber, spun yarn, and dyed filament with a cumulative capacity of
118,800 metric tons per annum in India. Ganesha’s rPET products are
components in the manufacture of textiles, such as T-shirts, body
warmers, functional textiles such as non-woven air filter fabric,
geo textiles, carpets, and car upholstery, and fillings for
pillows, duvets, and toys.
“CertainT provides brands and manufacturers with a real
strategic advantage that is truly sustainable, traceable and
trusted. Our India and Asia-based support teams for recycled PET
and other polymers facilitate CertainT’s commercial scale-up and
integration into customers’ supply chain,” stated Dr. James A.
Hayward, president, and CEO of Applied DNA Sciences.
About Ganesha Ecosphere Ltd
Ganesha Ecosphere Ltd is the largest Pet Recycling company in
India having 3 production facilities in north India. GESL produce a
wide range of RPSF in white, black and dope dyed colours in solid
and hollow conjugated suitable for Yarn spinning, nonwovens and
fibre fill applications.
GESL has also introduced certain speciality high value added
RPSF like Flame retardant fibre, Anti-Microbial and Bio-degradable
fibre.
GESL stocks are listed at NSE and BSE, Mumbai India.
About Applied DNA Sciences Applied DNA is commercializing
LinearDNA™, its proprietary, large-scale polymerase chain reaction
(“PCR”)-based manufacturing platform that allows for the
large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in
vitro diagnostics and preclinical nucleic acid-based drug
development and manufacturing market. The platform is used to
manufacture DNA for customers as components of in vitro diagnostic
tests and for preclinical nucleic acid-based drug development in
the fields of adoptive cell therapies (CAR T and TCR therapies),
DNA vaccines (anti-viral and cancer), RNA therapies, clustered
regularly interspaced short palindromic repeats (CRISPR) based
therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such
as supply chain security, anti-counterfeiting and anti-theft
technology. Key end-markets include textiles, pharmaceuticals and
nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based
technologies, the Company has also established safeCircle™, a
pooled COVID-19 testing program that is grounded in the Company’s
EUA-authorized Linea™ COVID-19 Assay Kit. safeCircle is designed to
look for infection within defined populations or communities
utilizing pooled testing methodologies that increase testing
efficiencies. The Company has also developed and intends to seek
EUA-authorization for its LineaTM SARS-CoV-2 Mutation Panel, an
assay-based panel for the detection of certain SARS-CoV-2 genetic
mutations.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the ticker
symbol ‘APDN,’ and its publicly traded warrants are listed on the
OTC exchange under the ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements The statements made by Applied
DNA in this press release may be "forward-looking" in nature within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements describe Applied DNA's future plans, projections,
strategies, and expectations, and are based on assumptions and
involve a number of risks and uncertainties, many of which are
beyond the control of Applied DNA. Actual results could differ
materially from those projected due to its history of net losses,
limited financial resources, limited market acceptance, including
Applied DNA's ability to successfully enter into commercial
contracts for the implementation of its CertainT® platform, the
uncertainties inherent in research and development, and various
other factors detailed from time to time in Applied DNA's SEC
reports and filings, including our Annual Report on Form 10-K filed
on December 17, 2020, and Quarterly Reports on Form 10-Q filed on
February 11, 2021, May 13, 2021, and August 12, 2021, and other
reports we file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211019005137/en/
Investor: Sanjay M. Hurry, 917-733-5573,
sanjay.hurry@adnas.com Program: MeiLin Wan, 631.240.8800,
meilin.wan@adnas.com B.P. Sultania, +91-5122555523,
gplpoly1@gmail.com Web: www.adnas.com Twitter:
@APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Sep 2023 to Sep 2024